BPaL regimen (Bedaquiline + Pretomanid + Linezolid)
Treatment for Extensively Drug Resistant Tuberculosis
Typical Dosage: Bedaquiline: 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks; Pretomanid: 200mg daily for 26 weeks; Linezolid: 600mg daily for 26 weeks (may be reduced to 300mg daily)
Effectiveness
88%
Safety Score
40%
Clinical Trials
1
Participants
1K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
Bedaquiline: 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks; Pretomanid: 200mg daily for 26 weeks; Linezolid: 600mg daily for 26 weeks (may be reduced to 300mg daily)
Time to Effect
3-6 months
Treatment Duration
6-9 months
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$3,500
Side Effect Mgmt:$2,000
Total Annual:$20,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$24,118
Cost per Remission
$24,118
Comparison vs Conventional individualized XDR-TB regimen (older drugs, injectables)
Cost Difference
$-15,000/year
Less expensive
QALY Difference
+0.75 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
BPaL regimen (Bedaquiline + Pretomanid + Linezolid) Outcomes
for Extensively Drug Resistant Tuberculosis
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov